CAMBRIDGE, MA, LifeMine Therapeutics, a biopharmaceutical company, announced the completion of a $175M Series C financing led by Fidelity Management & Research Company.
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, announced the completion of a $175 million Series C financing.
The financing was led by new investor Fidelity Management & Research Company, with participation by additional new investors Invus and 3W Partners Capital; GlaxoSmithKline (GSK) also joined the round as a strategic partner. Existing investors, including GV, Arch Venture Partners, Blue Pool Capital and MRL Ventures Fund, also participated.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about